Combivent UDV

Combivent UDV

ipratropium bromide + salbutamol

Manufacturer:

Boehringer Ingelheim

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Ipratropium Br 0.5 mg, salbutamol sulphate 2.5 mg
Indications/Uses
Reversible bronchospasm associated w/ obstructive pulmonary disease.
Dosage/Direction for Use
Adult & childn >12 yr Acute attacks 1 unit dose vial. Maintenance 1 unit dose vial tid-qid.
Contraindications
Hypersensitivity to atropine or its derivatives. Hypertrophic obstructive cardiomyopathy, tachyarrhythmia.
Special Precautions
Underlying severe heart disease, hypokalemia, uncontrolled DM, recent MI, severe organic heart or vascular disorders, hyperthyroidism, phaeochromocytoma, narrow-angle glaucoma, prostatic hypertrophy, bladder-neck obstruction, cystic fibrosis. Pregnancy. Avoid contact w/ eyes.
Adverse Reactions
Headache, throat irritation, cough, dry mouth, GI motility disorders (constipation, diarrhea, vomiting), nausea & dizziness.
Drug Interactions
Xanthine derivatives, glucocorticoids, steroids, diuretics, digoxin, β-blockers, MAOIs, TCA, halogenated hydrocarbon anaesth.
ATC Classification
R03AL02 - salbutamol and ipratropium bromide ; Belongs to the class of combination of adrenergics with anticholinergics, that may also include a corticosteroid. Used in the treatment of obstructive airway diseases.
Presentation/Packing
Form
Combivent UDV inhalation soln
Packing/Price
(unit dose) 2.5 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in